Kennedy Capital Management LLC Takes Position in Inotiv, Inc. (NASDAQ:NOTV)

Kennedy Capital Management LLC bought a new stake in Inotiv, Inc. (NASDAQ:NOTV - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,268,098 shares of the company's stock, valued at approximately $5,250,000. Kennedy Capital Management LLC owned approximately 4.88% of Inotiv at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of NOTV. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Inotiv in the 4th quarter valued at approximately $60,000. Virtu Financial LLC bought a new stake in Inotiv in the fourth quarter worth approximately $76,000. LPL Financial LLC acquired a new position in shares of Inotiv during the 4th quarter worth $136,000. AlphaCentric Advisors LLC bought a new position in shares of Inotiv during the 4th quarter valued at $163,000. Finally, American Century Companies Inc. acquired a new stake in shares of Inotiv in the 4th quarter valued at $163,000. 18.17% of the stock is owned by institutional investors and hedge funds.

Inotiv Stock Down 0.6 %

NASDAQ NOTV traded down $0.01 during trading on Friday, hitting $1.64. 515,713 shares of the company traded hands, compared to its average volume of 566,799. Inotiv, Inc. has a 12 month low of $1.15 and a 12 month high of $6.48. The business has a fifty day simple moving average of $2.85 and a 200 day simple moving average of $3.24. The company has a market capitalization of $55.30 million, a P/E ratio of -0.36 and a beta of 3.96. The company has a current ratio of 1.57, a quick ratio of 1.28 and a debt-to-equity ratio of 2.31.

Inotiv (NASDAQ:NOTV - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.10). Inotiv had a negative net margin of 25.40% and a negative return on equity of 15.41%. As a group, sell-side analysts predict that Inotiv, Inc. will post -0.79 EPS for the current year.

Insider Transactions at Inotiv

In related news, CEO Robert Jr. Leasure sold 22,700 shares of Inotiv stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $4.15, for a total transaction of $94,205.00. Following the sale, the chief executive officer now directly owns 1,030,209 shares of the company's stock, valued at $4,275,367.35. This trade represents a 2.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 108,311 shares of company stock worth $425,330. Insiders own 7.80% of the company's stock.

Inotiv Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.